Anti-VEGF Therapy

Overview: VEGF and Ocular Neovascularization

Vascular endothelial growth factor, VEGF-A in particular, drives most pathological angiogenesis and vascular leakage in the eye. Hypoxic or ischemic retinal, choroidal, and corneal tissue upregulates VEGF-A secretion. VEGF-A binds VEGFR-1 and VEGFR-2 on vascular endothelium, stimulating endothelial proliferation, migration, and increased permeability of existing vessels. One pathway accounts for choroidal neovascularization in age-related macular degeneration (AMD), macular edema from diabetic retinopathy and retinal vein occlusion, and retinal neovascularization in proliferative diabetic retinopathy.

Anti-VEGF therapy is intravitreal injection of an agent that binds and neutralizes VEGF before it can reach its receptors. It turned what had been an essentially untreatable cause of central vision loss into a manageable disease. Before these agents existed, neovascular (wet) AMD reliably progressed to severe vision loss; their introduction ranks among the most consequential therapeutic developments in modern ophthalmology.

Direct intravitreal injection delivers the drug straight into the vitreous cavity, from where it diffuses to the retina and choroid. Local concentrations reach far higher than any systemic route could achieve, and systemic exposure is reduced, though not eliminated.

The Agents

Pegaptanib (Macugen)

Pegaptanib was the first anti-VEGF agent approved for ocular use, and it works differently from everything that followed it. It is a pegylated RNA aptamer that binds only the heparin-binding VEGF165 isoform, rather than blocking all VEGF-A isoforms. That isoform selectivity is thought to explain its comparatively modest efficacy next to later pan-VEGF-A agents, and pegaptanib has largely been superseded in clinical practice.

Ranibizumab (Lucentis)

Ranibizumab is a recombinant, humanized monoclonal antibody Fab fragment, not a full antibody, that binds all isoforms of VEGF-A. Its smaller size, 48 kDa versus 148 kDa for a full antibody like bevacizumab, was engineered to improve retinal penetration after intravitreal injection.

Bevacizumab (Avastin): Off-Label Use

Bevacizumab is a full-length anti-VEGF-A monoclonal antibody approved for systemic use in oncology (metastatic colorectal cancer). Ophthalmologists use it off-label intravitreally at a far lower cost than ranibizumab. It is a different molecule entirely, a full antibody rather than a Fab fragment, yet head-to-head trials established that its ocular efficacy is equivalent (see CATT, below).

Aflibercept (Eylea): The "VEGF Trap"

Aflibercept is structurally distinct from the antibody-based agents above. It is a recombinant fusion protein, not an antibody or antibody fragment, incorporating immunoglobulin domain 2 of VEGFR-1 (high-affinity binding to VEGF-A, VEGF-B, and placental growth factor, PlGF) and immunoglobulin domain 3 of VEGFR-2 (additional VEGF-A binding), fused to an IgG1 Fc region. The combination acts as a high-affinity decoy receptor, a "VEGF trap," binding VEGF-A, VEGF-B, and PlGF with higher affinity than ranibizumab has for VEGF-A alone. Its picomolar-range binding exceeds even the naturally occurring VEGF receptors.

Brolucizumab (Beovu)

Brolucizumab is a small single-chain variable fragment (scFv), only about 26 kDa, smaller than ranibizumab's Fab fragment. That small size allows a much higher molar concentration of active drug in a standard injection volume, the pharmacologic rationale for its longer dosing intervals. Post-marketing surveillance revealed a higher-than-expected rate of intraocular inflammation and retinal vasculitis with brolucizumab, prompting updated safety guidance around its use.

Faricimab (Vabysmo): Dual VEGF-A/Ang-2 Blockade

Faricimab introduced a genuinely new mechanism to the class. It is a bispecific antibody that targets VEGF-A and Angiopoietin-2 (Ang-2) simultaneously. VEGF-A blockade reduces angiogenesis and vascular permeability as with the other agents. Ang-2 blockade works on a complementary pathway: Ang-2 normally destabilizes retinal vessels by competing with Ang-1 for binding at the Tie2 receptor, so neutralizing it stabilizes the vasculature directly. The dual mechanism provides additive vessel stabilization and has enabled extended dosing intervals of up to every 16 weeks in some patients.

Indications and Delivery

Anti-VEGF therapy was first approved for neovascular (exudative/wet) AMD, where choroidal neovascularization causes rapid central vision loss. This is the indication that established the drug class: early trials showed visual acuity gains that reversed a course of vision loss previously considered inevitable. Approved indications have since expanded to diabetic macular edema (DME), branch and central retinal vein occlusion, myopic choroidal neovascularization, and diabetic retinopathy more broadly. Anti-VEGF therapy has no role in infectious conditions like bacterial keratitis. Its entire mechanism is neutralizing a growth factor, not fighting a pathogen.

For DME specifically, anti-VEGF is considered first-line over macular laser in eyes with center-involving DME with reduced visual acuity; non-center-involving DME, or DME without functional visual impairment, may instead be monitored or treated with laser depending on severity.

The injection itself carries a small procedural risk, separate from the systemic effects below. Large multicenter series put post-injection endophthalmitis at roughly 1 in 2,000 injections, well under the 1% ceiling reported by earlier meta-analyses, and coagulase-negative Staphylococcus causes most culture-positive cases. Applying povidone-iodine to the ocular surface immediately before injection is the one prophylactic step with real evidence behind it; routine antibiotic drops do not lower the rate and are not recommended. Retinal detachment, sustained intraocular pressure elevation, and hemorrhage round out the less common but recognized local complications.

Dosing Regimens and Tachyphylaxis

Treat-and-extend (T&E) has become the dominant real-world dosing strategy, distinct from both fixed monthly dosing and PRN (as-needed) dosing. Rather than holding to a fixed interval or waiting for a measurable drop in visual acuity, T&E lengthens the interval between injections after a stable visit and shortens it again if disease activity recurs. It reduces total injection burden compared to rigid monthly dosing while avoiding the undertreatment risk and heavy monitoring burden of pure PRN dosing.

A separate and unrelated phenomenon is tachyphylaxis, a reduced clinical response to repeated anti-VEGF injections over time in some patients. The most widely proposed mechanism is not neutralizing-antibody formation or reduced drug penetration, but upregulation of alternative angiogenic and inflammatory pathways (PDGF, FGF, Ang-2, IL-6, IL-8) that provide an escape route around VEGF blockade. This is the same biological rationale behind combination therapies like faricimab, which target more than one pathway at once.

Extended Delivery: PDS and Gene Therapy

The Port Delivery System (PDS) with ranibizumab, brand name Susvimo, takes a fundamentally different approach to reducing injection burden. Instead of repeated bolus injections, a small refillable reservoir is surgically implanted through a pars plana incision, releasing ranibizumab continuously by passive diffusion through a porous release element. The ARCHWAY trial demonstrated non-inferiority to monthly ranibizumab injections, with refill needed only about every 24 weeks.

Gene therapy approaches go a step further, aiming to make the eye's own cells produce anti-VEGF protein indefinitely rather than delivering the protein itself on a schedule. AAV-vector-based candidates deliver genes encoding an anti-VEGF Fab fragment (subretinal delivery) or aflibercept-like constructs (intravitreal delivery) to retinal cells. The goal is a single treatment providing years of continuous anti-VEGF protein expression, though these approaches remain in later-phase clinical trials rather than routine practice.

Systemic Safety

Landmark Trials

A handful of trials defined how this drug class is actually used today:

• CATT (Comparison of AMD Treatments Trials): established that bevacizumab and ranibizumab produce equivalent visual acuity outcomes at 1 and 2 years when dosed on the same schedule, the level-1 evidence underlying bevacizumab's widespread off-label use as a far cheaper alternative. Ranibizumab PRN dosing was equivalent to monthly dosing at 1 year, but monthly dosing gave modestly better acuity by 2 years (about 2.4 letters).
• VIEW 1 and VIEW 2: established the "2q8" aflibercept regimen. 2 mg aflibercept every 8 weeks, after three initial monthly loading doses, proved non-inferior to monthly ranibizumab for visual acuity in neovascular AMD, the first pivotal-trial evidence extending a dosing interval beyond monthly.
• PANORAMA: demonstrated that 2 mg aflibercept, dosed every 16 weeks after loading, significantly reduced the 2-year risk of progression to proliferative diabetic retinopathy or center-involving DME in eyes with moderately severe to severe non-proliferative diabetic retinopathy (NPDR) that did not yet have DME. This established anti-VEGF as a disease-modifying treatment for high-risk NPDR itself, not just an intervention for established macular edema.

Related Topics

Continue exploring Basic Sciences: